{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036404","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.229505+00:00","generated_at":"2026-05-31T10:41:01.201028+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Gyre Therapeutics appoints David M. Epstein, Ph.D. to Board of Directors","bullets":["David Epstein appointed as Class II director effective Aug 6, 2024; serves on Audit and Compensation Committees.","Epstein co-founded Black Diamond Therapeutics (BDTX) and PairX Bio; former CSO of OSI Pharmaceuticals.","Rodney Nussbaum appointed as Chair of Audit Committee on same date."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036404","json":"https://secwatch.observer/filing/0001140361-24-036404.json","markdown":"https://secwatch.observer/filing/0001140361-24-036404.md","text":"https://secwatch.observer/filing/0001140361-24-036404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124036404/0001140361-24-036404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124036404/ef20033805_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:41:01.201028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88ee80470f","claim":"David Epstein was appointed as Class II director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"the Board of Directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”) appointed David Epstein, Ph.D. as a Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124036404/0001140361-24-036404-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}